Abiopharma

🔍 Dandekar Atul (Executive)

Company: Maze Therapeutics, Inc. (MAZE)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 7,500 shares of Common Stock at $10.42 per share (Direct)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,003.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,500 shares of Common Stock at $25.3732 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,503.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 7,500 shares of Stock Option (Right to Buy) at $10.42 per share (Derivative)
  Date: 2026-04-29 | Code: M | Expires: 2031-04-11 | equity_swap_involved: 0 | shares_owned_after: 44,143.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.08 to $25.77 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.